{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-295562","form_type":"8-K/A","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.990729+00:00","generated_at":"2026-06-07T13:13:40.984404+00:00","sec_items":["2.02","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Pfizer completes $43B acquisition of Seagen; Seagen becomes wholly owned subsidiary","bullets":["Acquisition closed Dec 14, 2023; $229 per share in cash for total enterprise value approx. $43 billion.","Adds Seagen's four approved medicines (ADCETRIS, PADCEV, TIVDAK, TUKYSA) and ADC technology.","Pfizer's oncology pipeline doubled to 60 programs across multiple modalities.","To address FTC concerns, Pfizer irrevocably donated U.S. royalty rights from Bavencio (avelumab) to AACR.","Pfizer's oncology portfolio now includes over 25 approved medicines and biosimilars across >40 indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-295562","json":"https://secwatch.observer/filing/0001193125-23-295562.json","markdown":"https://secwatch.observer/filing/0001193125-23-295562.md","text":"https://secwatch.observer/filing/0001193125-23-295562.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000119312523295562/0001193125-23-295562-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000119312523295562/d612444d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:13:40.984404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c7160259368917f75f0c9bd3a9e5a73d63e3b2d","claim":"PFIZER INC completed an acquisition involving Seagen Inc. for $229 in cash per share, for a total enterprise value of approximately $43 billion (closed 2023-12-14).","evidence_excerpt":"Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000119312523295562/0001193125-23-295562-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Seagen Inc."},{"label":"Consideration","value":"$229 in cash per share, for a total enterprise value of approximately $43 billion"},{"label":"Closing","value":"2023-12-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}